May 10, 2007 (Las Vegas) — Rituximab can be safely infused using a rapid 90-minute protocol in patients with non-Hodgkin's lymphoma, according to a presentation made at the annual meeting of the ...

Medicare Part B (medical insurance) may cover Rituxan (rituximab) infusions. This is because medical professionals typically administer the medication in a medical setting on an outpatient basis.

No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...

Please provide your email address to receive an email when new articles are posted on . The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically ...

A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past ...

Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...

Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...

THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...

LONDON (Reuters) - Lymphoma patients who continue regular infusions of Genentech Inc and Biogen Idec's Rituxan after chemotherapy may live longer than patients who stop, Israeli researchers said on ...

—Rituxan is the first and only FDA-approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis— “Rituxan is now approved ...